Details of the Drug Combination

General Information of Drug Combination (ID: DCC17X1)

Drug Combination Name
CA4P AZD8055
Indication
Disease Entry Status REF
Glioblastoma Investigative [1]
Component Drugs CA4P   DM9R0ZL AZD8055   DM7L8SG
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: JHH-136
Zero Interaction Potency (ZIP) Score: 50.626
Bliss Independence Score: 52.389
Loewe Additivity Score: 2.197
LHighest Single Agent (HSA) Score: 5.703

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CA4P
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Ovarian cancer 2C73 Phase 2 [2]
Indication(s) of AZD8055
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1/2 [3]
AZD8055 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7714).
4 Clinical pipeline report, company report or official report of AstraZeneca (2009).